Longitudinal Effects of Glecaprevir/Pibrentasvir on Liver Function, Fibrosis, and Hepatocellular Carcinoma Risk in Chronic Hepatitis C: A Prospective Multicenter Cohort Study.

ABSTRACT: Background and Aims: Glecaprevir/pibrentasvir achieves sustained virologic response (SVR) rates above 95% in chronic hepatitis C (CHC). Nevertheless, the residual risk of hepatocellular carcinoma (HCC) after SVR, especially in patients with advanced liver disease, has not been fully defined. We prospectively evaluated longitudinal changes in liver function and fibrosis and sought predictors of post-SVR HCC in a real-world multicenter cohort. Methods: A total of 395 CHC patients who attained SVR with glecaprevir/pibrentasvir were followed prospectively. Liver function tests, noninvasive fibrosis indices, and clinical outcomes were recorded at predefined intervals. Cox proportional hazards regression identified factors associated with incident HCC. Results: Over a median

SUBMITTER: Kim JH 

PROVIDER: S-EPMC12471995 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature